• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化肺部指南:肺部急性加重的治疗

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

作者信息

Flume Patrick A, Mogayzel Peter J, Robinson Karen A, Goss Christopher H, Rosenblatt Randall L, Kuhn Robert J, Marshall Bruce C

机构信息

Department of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

出版信息

Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.

DOI:10.1164/rccm.200812-1845PP
PMID:19729669
Abstract

The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.

摘要

囊性纤维化肺病的自然病程是一个慢性进展过程,其间症状会间歇性急性加重,这种情况常被称为急性肺部加重期。这些加重期通常需要医学干预。基于有效性和安全性的现有证据推荐合适的治疗方法很重要。因此,囊性纤维化基金会成立了一个委员会,以确定与肺部加重期相关的关键问题,采用循证方法审查临床证据,并向临床医生提供建议。希望这些指南对临床医生治疗囊性纤维化患者有所帮助。

相似文献

1
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.囊性纤维化肺部指南:肺部急性加重的治疗
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.
2
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.囊性纤维化肺部指南:维持肺部健康的慢性药物治疗
Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. doi: 10.1164/rccm.200705-664OC. Epub 2007 Aug 29.
3
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.囊性纤维化肺部治疗指南:肺部并发症:咯血和气胸。
Am J Respir Crit Care Med. 2010 Aug 1;182(3):298-306. doi: 10.1164/rccm.201002-0157OC.
4
Pulmonary exacerbations in cystic fibrosis.囊性纤维化中的肺部恶化。
Curr Opin Pulm Med. 2011 Nov;17(6):442-7. doi: 10.1097/MCP.0b013e32834b8c04.
5
Efficacy of β-lactams as single agents for treating severe pulmonary exacerbations during pregnancy in cystic fibrosis.β-内酰胺类药物作为单药治疗囊性纤维化孕妇严重肺部加重期的疗效。
Am J Respir Crit Care Med. 2012 Dec 15;186(12):1310-1. doi: 10.1164/ajrccm.186.12.1310.
6
Cystic fibrosis pulmonary guidelines: airway clearance therapies.囊性纤维化肺部指南:气道清除疗法
Respir Care. 2009 Apr;54(4):522-37.
7
The clinical approach to lung disease in patients with cystic fibrosis.囊性纤维化患者肺部疾病的临床治疗方法。
Semin Respir Crit Care Med. 2009 Oct;30(5):505-13. doi: 10.1055/s-0029-1238909. Epub 2009 Sep 16.
8
A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.一项关于囊性纤维化患者中使用抗假单胞菌β-内酰胺类抗生素治疗的调查。
Pediatr Pulmonol. 2011 Oct;46(10):987-90. doi: 10.1002/ppul.21467. Epub 2011 Apr 25.
9
Optimizing outcomes of pulmonary exacerbations in cystic fibrosis.优化囊性纤维化肺部恶化的转归。
Curr Opin Pulm Med. 2018 Nov;24(6):606-611. doi: 10.1097/MCP.0000000000000519.
10
Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review.成年囊性纤维化患者肺部加重期的治疗:综述
Hosp Pract (1995). 2010 Feb;38(1):26-34. doi: 10.3810/hp.2010.02.287.

引用本文的文献

1
Personalized tobramycin dosing in children with cystic fibrosis: an AUC-guided approach.囊性纤维化患儿的妥布霉素个体化给药:一种基于药时曲线下面积(AUC)指导的方法。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0027825. doi: 10.1128/aac.00278-25. Epub 2025 Jul 23.
2
Wideband Middle-Ear Measures in Aminoglycoside-Exposed Adults with Cystic Fibrosis.患有囊性纤维化的氨基糖苷类药物暴露成人的宽带中耳测量
Ear Hear. 2025 Jun 30. doi: 10.1097/AUD.0000000000001693.
3
Clinical Significance of the 5T;12TG Genotype in Pediatric CFSPID: A Retrospective Study.
5T;12TG基因型在儿童CFSPID中的临床意义:一项回顾性研究
Children (Basel). 2025 Jun 14;12(6):778. doi: 10.3390/children12060778.
4
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.囊性纤维化微生物群导向的抗生素治疗急性加重期试验结果分层研究(CFMATTERS):一项多中心随机对照试验的结果
Eur Respir J. 2025 Aug 8;66(2). doi: 10.1183/13993003.02443-2024. Print 2025 Aug.
5
Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients.成人囊性纤维化患者急性肺部加重期治疗的万古霉素监测
Pulm Med. 2025 May 28;2025:5683225. doi: 10.1155/pm/5683225. eCollection 2025.
6
State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists.最新综述:囊性纤维化患者护理的变革性变化:对传染病专家的启示
Clin Infect Dis. 2025 Jun 4;80(5):e65-e77. doi: 10.1093/cid/ciaf009.
7
A Joint Model for (Un)Bounded Longitudinal Markers, Competing Risks, and Recurrent Events Using Patient Registry Data.一种使用患者登记数据的(无)界纵向标志物、竞争风险和复发事件的联合模型。
Stat Med. 2025 Apr;44(8-9):e70057. doi: 10.1002/sim.70057.
8
The Aging Patient with Cystic Fibrosis.患有囊性纤维化的老年患者
Drugs Aging. 2025 Apr 24. doi: 10.1007/s40266-025-01207-3.
9
Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring bla and crpP causing bronchiectasis.携带bla和crpP基因的难治性耐药铜绿假单胞菌分离株的基因组流行病学及特征分析,该分离株导致支气管扩张。
Sci Rep. 2025 Apr 15;15(1):12932. doi: 10.1038/s41598-025-95950-7.
10
Improving ototoxicity monitoring in patients receiving aminoglycosides using a novel digital approach: a quality improvement project.使用新型数字方法改善接受氨基糖苷类药物治疗患者的耳毒性监测:一项质量改进项目。
BMJ Open Qual. 2025 Apr 15;14(2):e002847. doi: 10.1136/bmjoq-2024-002847.